Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.
OBJECTIVE
To compare the effectiveness of sequential therapy for Helicobacter pylori (H. pylori) infection with that of triple therapy of varying durations.


METHODS
The 460 patients enrolled in this study had H. pylori-associated gastritis or a gastric or duodenal ulcer. After screening, H. pylori-infected patients were randomly assigned to receive either conventional triple therapy for 7, 10 or 14 d, or a new 10-d sequential therapy. Each of the 4 treatment groups included 115 patients. The outcomes of eradication therapy were assessed 4 wk after treatment by the urea breath test and histology.


RESULTS
The overall eradication rate was 81.0%, and eradication rates were 75.7% for 7-d conventional triple therapy, 81.9% for 10-d conventional triple therapy, 84.4% for 14-d conventional triple therapy, and 82.0% for 10-d sequential therapy. Neither intention-to-treat analysis nor per protocol analysis showed significant differences in eradication rates using sequential therapy or the standard triple therapy (P = 0.416 and P = 0.405, respectively).


CONCLUSIONS
There are no significant differences between 10-d sequential eradication therapy for H. pylori and any duration of standard triple treatment in Korean patients.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Digestive Disease and Nutrition, Korea University College of Medicine, Seoul 136-705, South Korea. drchunhj@chol.com
Hyuk Soon
HS
Choi
Hoon Jai
HJ
Chun
Sang Hoon
SH
Park
Bora
B
Keum
Yeon Seok
YS
Seo
Yong Sik
YS
Kim
Yoon-Tae
YT
Jeen
Soon Ho
SH
Um
Hong Sik
HS
Lee
Chang Duck
CD
Kim
Ho Sang
HS
Ryu
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000477:Alkylating Agents / Q000008:administration & dosage*; D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D017291:Clarithromycin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000150:complications / Q000188:drug therapy; D005260:Female; D005756:Gastritis / Q000150:complications / Q000188:drug therapy; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D064750:Rabeprazole; D013276:Stomach Ulcer / Q000150:complications / Q000188:drug therapy; D014011:Tinidazole / Q000008:administration & dosage
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000477:Alkylating Agents; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D014011:Tinidazole; D064750:Rabeprazole; D000658:Amoxicillin; D017291:Clarithromycin